- ISIN
- US87164F1057
- CUSIP
- 87164F105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 3, 2016
Highlights
- EPS (TTM)
- -$3.75
- Total Revenue (TTM)
- $217.17M
- Gross Profit (TTM)
- $208.46M
- EBITDA (TTM)
- -$171.20M
- Year Range
- $8.59 - $25.59
- Target Price
- $39.33
- ROA (TTM)
- -51.46%
- ROE (TTM)
- -584.42%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SNDX Performance Chart
Syndax Pharmaceuticals, Inc. (SNDX) is down 8.0% since the beginning of the year. At $19 per share, SNDX is trading 24.5% below its 52-week high of $26. Investors who bought $1,000 worth of SNDX shares 5 years ago would now be looking at an investment worth $1,070.
Loading charts...
Returns By Period
Syndax Pharmaceuticals, Inc. (SNDX) has returned -8.04% so far this year and 103.80% over the past 12 months. Over the last ten years, SNDX has returned 6.13% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Syndax Pharmaceuticals, Inc.
- 1D
- 1.68%
- 1M
- -3.11%
- YTD
- -8.04%
- 6M
- -10.06%
- 1Y
- 103.80%
- 3Y*
- -2.62%
- 5Y*
- 1.36%
- 10Y*
- 6.13%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SNDX Monthly Returns History
Based on dividend-adjusted daily data since Mar 3, 2016, SNDX's average daily return is +0.12%, while the average monthly return is +2.03%. At this rate, an investment would double in approximately 2.9 years.
Historically, 52% of months were positive and 48% were negative. The best month was Aug 2025 with a return of +64.6%, while the worst month was Oct 2018 at -40.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, SNDX closed higher 49% of trading days. The best single day was Apr 28, 2020 with a return of +69.4%, while the worst single day was Apr 20, 2021 at -30.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.33% | 6.89% | 7.60% | -8.26% | -8.59% | -1.38% | -8.04% | ||||||
| 2025 | 7.19% | 10.37% | -21.45% | 15.18% | -25.51% | -11.15% | 5.93% | 64.62% | -5.79% | -10.95% | 44.67% | 6.00% | 58.93% |
| 2024 | -5.18% | 14.40% | 1.54% | -11.22% | -8.80% | 6.54% | 10.57% | -9.47% | -6.33% | -2.03% | -11.35% | -20.93% | -38.82% |
| 2023 | 12.77% | -11.67% | -16.69% | -2.70% | -2.82% | 4.81% | 1.86% | -13.18% | -21.56% | -3.03% | 18.22% | 29.83% | -15.09% |
| 2022 | -25.35% | -4.59% | 11.48% | -3.51% | -1.61% | 16.61% | 5.87% | 15.91% | 1.78% | -4.45% | 4.36% | 6.22% | 16.26% |
| 2021 | -9.89% | 21.81% | -8.40% | -28.71% | 15.24% | -6.53% | -15.08% | 19.96% | 9.26% | 1.78% | -17.89% | 37.07% | -1.57% |
Benchmark Metrics
Syndax Pharmaceuticals, Inc. has an annualized alpha of 14.23%, beta of 1.09, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since March 03, 2016.
- This stock participated in 71.68% of S&P 500 Index downside but only 47.02% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 14.23%
- Beta
- 1.09
- R²
- 0.08
- Upside Capture
- 47.02%
- Downside Capture
- 71.68%
Return for Risk
Risk / Return Rank
SNDX ranks 85 for risk / return — in the top 85% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Syndax Pharmaceuticals, Inc. (SNDX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SNDX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.19 | ||
| Sortino ratioReturn per unit of downside risk | -0.02 | ||
| Omega ratioGain probability vs. loss probability | 1.31 | 1.37 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | 3.21 | 2.78 | +0.42 |
| Martin ratioReturn relative to average drawdown | 9.41 | 12.44 | -3.03 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Syndax Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Syndax Pharmaceuticals, Inc. was 78.98%, occurring on Dec 24, 2018. Recovery took 337 trading sessions.
The current Syndax Pharmaceuticals, Inc. drawdown is 33.33%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Rate-hike selloffLate 2018 | -78.98%Dec 2018 | 2y 4mo | 1y 4mo | 3y 8moAug 2016 - Apr 2020 |
2025 bear market2025 | -69.88%Jul 2025 | 2y 5mo | — | 3y 4moFeb 2023 - now |
2021 bear market2021 | -49.24%Apr 2021 | 3mo 29d | 1y 8mo | 2y 21dDec 2020 - Jan 2023 |
2016 bear market2016 | -45.42%Jun 2016 | 2mo 21d | 1mo 27d | 4mo 18dApr 2016 - Aug 2016 |
2020 bear market2020 | -36.18%Jul 2020 | 2mo 7d | 3mo 14d | 5mo 21dMay 2020 - Nov 2020 |
Drawdown Indicators
| SNDX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.98% | -56.78% | -22.20% |
Max Drawdown (1Y)Largest decline over 1 year | -32.56% | -9.10% | -23.46% |
Max Drawdown (3Y)Largest decline over 3 years | -64.81% | -18.90% | -45.91% |
Max Drawdown (5Y)Largest decline over 5 years | -69.88% | -25.43% | -44.45% |
Max Drawdown (10Y)Largest decline over 10 years | -78.98% | -33.92% | -45.06% |
Current DrawdownCurrent decline from peak | -33.33% | -1.80% | -31.53% |
Average DrawdownAverage peak-to-trough decline | -35.80% | -10.71% | -25.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.10% | 2.03% | +9.07% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Syndax Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Syndax Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SNDX relative to other companies in the Biotechnology industry. Currently, SNDX has a P/S ratio of 5.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SNDX
Add Syndax Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SNDX